BiochemProbe — Life Science Research Reagents

Avotaciclib free base · Synonyms: BEY1107

Avotaciclib is an orally active cyclin-dependent kinase 1 inhibitor.

For research use only. Not for human or veterinary use.

Target CDK Apoptosis
Research area Cancer
Purity >98% Stock Inquire

Avotaciclib structure

CAS No.: 1983983-41-0

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
250 mg USD 725.00 BP-02287-250mg In stock Get quote
500 mg USD 1,125.00 BP-02287-500mg In stock Get quote
1 g USD 1,685.00 BP-02287-1g In stock Get quote
5 g Inquire BP-02287-5g In stock Inquire

Description

Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer.

Biological activity

Avotaciclib (0-64 μM; 48 h) can inhibit cell proliferation and promote apoptosis in radiotherapy-resistant non-small cell lung cancer cell lines, and the effect is better when combined with PV-1019

Identifiers

SMILES
OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3
InChIKey
VFVAQKKPFOPZEA-UHFFFAOYSA-N

Specifications

MW (average)
281.2727
Formula
C13H11N7O
CAS No.
1983983-41-0
Physical state
Solid
Color
Light yellow to yellow
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
-20°C, protect from light, stored under nitrogen

Solubility

Soluble in DMSO : 100 mg/mL

References

[1].Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.
[2].Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17(2): 100900.

Same target

Search CDK

Same research area

Search Cancer

Recently viewed